We can’t show the full text here under this license. Use the link below to read it at the source.
Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders
Potential of glucagon-like peptide 1 drugs to treat metabolic disorders
AI simplified
Page updated
Abstract
Resmetirom is the first treatment approved by the FDA specifically aimed at reducing liver fibrosis in metabolic-associated steatohepatitis.
- Glucagon-like peptide 1 receptor agonists may be effective for metabolic dysfunction-associated steatotic liver disease (MASLD), particularly when used in combination therapy.
- Resmetirom acts directly on liver pathways as a thyroid hormone beta-selective agonist, enhancing its therapeutic potential for liver fibrosis.
- Lifestyle modifications, including dietary changes and regular exercise, are essential for improving outcomes in liver disease management.
- Incorporating lifestyle factors into treatment strategies could reduce the need for medications and improve their efficacy.
AI simplified